Bristol-Myers Squibb Company

NYSE: BMY
$48.85
-$0.14 (-0.3%)
Closing price April 24, 2024
Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for a range of serious diseases. With a rich history dating back to 1887, it specializes in treatments across hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience fields. Its portfolio includes notable drugs like Eliquis, Opdivo, and Sprycel, targeting conditions from cancer to multiple sclerosis. The company markets its products to a variety of clients, including hospitals, pharmacies, and government agencies, aiming to improve patient health outcomes worldwide.
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Monday afternoon's analyst upgrades and downgrades included Bristol-Myers Squibb, Intel, Merck, Newell Brands, Snap, Spotify Technology and Tilray.
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal market...
These six top Goldman Sachs stock picks all pay healthy dividends and offer great total return potential and less potential volatility in a very overbought stock market that may be poised for a...
Tuesday's top analyst upgrades and downgrades included AbbVie, Alibaba, American Airlines, AT&T, Chipotle Mexican Grill, JD.com, Kimberly-Clark, Pfizer, Starbucks and Weyerhaeuser.
Warren Buffett reduced Berkshire Hathaway's holdings in 13 stocks during the first quarter of this year. Here's how eight of those stocks have performed so far in the second quarter.
24/7 Wall St. screened the BofA Securities research universe looking for Buy-rated stocks in the so-called defensive growth sectors, such as consumer staples and big pharmaceuticals, and found five...
Even though the economy is starting to open up, it may be time for investors to move to more defensive positions. These BofA Securities stock picks pay dependable dividends and can soften the blow if...
These five Goldman Sachs high-conviction stock picks look like outstanding total return ideas now. They are positioned well for the rest of 2021 and beyond, and they make sense for growth and income...
Friday's top analyst upgrades and downgrades included AvalonBay Communities, Bristol-Myers Squibb, Carrier, Comcast, CyrusOne, DraftKings, Nvidia and Textron.
Tuesday's top analyst upgrades and downgrades included Beyond Meat, Booking, Bristol-Myers Squibb, Cloudflare, FedEx, JetBlue Airways, Nvidia, PepsiCo, Square and Zscaler.
These five top picks from the Goldman Sachs America's Conviction List look poised for great total return potential and less potential volatility in a very overbought stock market. They all pay...
The analysts at BofA Securities have added an IT services giant to the firm's US 1 List of top stock recommendations. Plus, here are three additional ideas that make sense for growth investors now
BofA Securities says that, given current market conditions, it makes sense for investors to move to safer stocks that pay dividends. These five look like great places to park some portfolio money now...